Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | PTGES | O14684 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13949905 | 0.93 | ALDH1A1 (0.46) | HSD11B1ALDH1A1LMNAPTGESL3MBTL1 | |
| SCHEMBL6083995 | 0.86 | ALDH1A1 (0.64) | HSD11B1ALDH1A1LMNAPTGESL3MBTL1 | |
| SCHEMBL3318109 | 0.86 | ALDH1A1 (0.54) | HSD11B1ALDH1A1LMNAPTGESL3MBTL1 | |
| SCHEMBL6084415 | 0.85 | P2RX7 (0.51) | HSD11B1ALDH1A1LMNANPC1TP53 | |
| SCHEMBL13949720 | 0.85 | RAB9A (0.43) | HSD11B1ALDH1A1LMNAL3MBTL1RAB9A | |
| SCHEMBL3319841 | 0.83 | GAA (0.57) | HSD11B1ALDH1A1LMNAL3MBTL1RAB9A | |
| SCHEMBL1770376 | 0.83 | HSD11B1 (0.54) | HSD11B1ALDH1A1LMNAPTGESL3MBTL1 | |
| SCHEMBL6084262 | 0.80 | ALDH1A1 (0.54) | HSD11B1ALDH1A1LMNAPTGESL3MBTL1 | |
| SCHEMBL11678560 | 0.80 | HTT (0.57) | HSD11B1ALDH1A1LMNAPTGESL3MBTL1 | |
| SCHEMBL6085750 | 0.76 | ALDH1A1 (0.58) | HSD11B1ALDH1A1LMNAPTGESHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299249-B2 | Method for producing TETA by means of EDDN | BASF SE (DE) | 2012-10-30 | — | — | US | disclosed |
| US-20100121064-A1 | NOVEL METHOD FOR PRODUCING TETA BY MEANS OF EDDN | BASF SE (DE) | 2010-05-13 | — | — | US | disclosed |
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121064-A1 | NOVEL METHOD FOR PRODUCING TETA BY MEANS OF EDDN | TET1, TET3, TET2 | HSD11B1 696/4885ALDH1A1 576/4885LMNA 824/4885 |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | HSD11B1 3/4885ALDH1A1 437/4885LMNA 4234/4885 |
| US-20100120789-A1 | Compound | NR0B2, NR0B1, NR4A1 | HSD11B1 73/4885ALDH1A1 3143/4885LMNA 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.